|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
|
|---|---|---|---|
| Sales | |||
| Cost of Sales | |||
| Gross profit | |||
| Research and development expenses | |||
| Selling and marketing expenses | |||
| General and administrative expenses | |||
| Initial public offering expenses | |||
| Operating loss | |||
| Change in fair value of convertible notes | |||
| Change in fair value of derivative warrant liabilities | |||
| Issuance expenses attributable to derivate warrant liability | |||
| Interest expenses on related party loan | |||
| Other finance income, net | |||
| Net loss and comprehensive loss | |||
| Net loss per ordinary share, basic (in Dollars per share) | |||
| Net loss per ordinary share, diluted (in Dollars per share) | |||
| Weighted-average number of ordinary shares outstanding, basic (in Shares) | |||
| Weighted-average number of ordinary shares outstanding, diluted (in Shares) |
Loading...
